Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO
Biotech firm also plans to expand its headcount to about 300 in next five years
Add BT as a preferred source
Singapore
SINGAPORE-BASED Prestige Biopharma expects an implied market capitalisation of between 1.8 trillion won and 1.93 trillion won (S$2.2 billion to S$2.3 billion) in its upcoming initial public offering (IPO) on the Korea Exchange (KRX), the company told The Business Times.
As it looks to list early this year, the biotech firm also plans to expand its headcount from the current 70 to about 300 staff, possibly in the next five years, its chief executive Lisa Park told BT.
TRENDING NOW
Japan Home closing outlets; staff say Valu$ taking over operations
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
From sales executive to DBS chairman: A look at banking veteran Peter Seah’s career
Timah Partners lands S$60 million facility from lenders including UOB, RHB
